We apply our innovative in vitro embryonic stem (ES) cell technologies to discover and develop new generation drugs and protein biologics, both internally and through strategic collaborations with the pharmaceutical and biotechnology industries.

  Our ES cell technologies enable the discovery and validation of both classical disease- drug targets and pathway-specific proteins that are potential biological drug molecules. We are focusing our ES cell technologies on high-throughput drug discovery screens in the diabetes and neurological disease markets.

  Our ES cell technologies provide predictive human ES cell-based heart and liver cell assay systems that address the limitations of current biological systems and focus on the two most relevant cell types for pharmaceutical toxicity testing.